Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: The PROGRESS study, 48-week results

HIV Clinical Trials

Volumn 12, Issue 5, 2011, Pages 255-267

  Reynes, Jacques ^a   Lawal, Adebayo ^b   Pulido, Federico ^c   Soto Malave, Ruth ^b,d   Gathe, Joseph ^e   Tian, Min ^b   Fredrick, Linda ^b   Podsadecki, Thomas ^b   Nilius, Angela ^b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b Department R48U AP30 3 ^*  (Puerto Rico)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^e Therapeutic Concepts   (United States)

Author keywords

emtricitabine; HIV 1; lopinavir; NRTI sparing; raltegravir; tenofovir

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FANCONI RENOTUBULAR SYNDROME; FEMALE; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERLIPIDEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; TREATMENT RESPONSE;

ADENINE; ADULT; ALGORITHMS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VIRAL LOAD;

EID: 84255190565     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1205-255     Document Type: Article

References (20)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011. http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed July 7, 2011.
2. Muñoz de Benito RM, Arribas López JR. Tenofovir disoproxil fumarate-emtricitabine coformulation for oncedaily dual NRTI backbone. Expert Rev Anti Infect Ther. 2006;4(4):523-535.
3. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201. (Pubitemid 38917996)
4. McComsey GA, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection [106LB]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA.
5. Stellbrink H, Moyle G, Orkin C, et al. Assessment of safety and efficacy of abacavir/lamivudine and tenofovir/emtricitabine in treatment-naive HIV-1 infected subjects. ASSERT: 48-week result [PS10/1]. In: Program and abstracts of the 12th European AIDS Conference; November 11-14, 2009; Cologne, Germany.
6. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunoDeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36(8):1070-1073. (Pubitemid 36513295)
7. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35(3):269-273. (Pubitemid 38280652)
8. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23(6):689-696.
9. Gathe J, Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir- based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviralnaive subjects through 48 weeks. J Acquir Immune Defic Syndr. 2009;50(5):474-481.
10. Zajdenverg R, Podsadecki TJ, Badal-Faesen S, et al. Similar safety and Efficacy of once-and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks. J Acquir Immune Defic Syndr. 2010;54(2):143-151.
11. Kaletra [package insert]. North Chicago IL: Abbott Laboratories 2010.
12. Isentress [package insert]. Whitehouse Station, NJ: Merck & Co; 2010.
13. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and effi -cacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796-806.
14. Rhame F, Long M, Acosta A. RAL-KAL: pharmacokinetics of coadministered raltegravir and lopinavir-ritonavir in healthy adults [TuPE0075]. Paper presented at: 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.
15. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17(5):138-145.
16. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry antiretroviral drugs using plasma HIV RNA measurements -clinical considerations for accelerated and traditional approval. 2002. http://www. fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf.
17. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095-2106. (Pubitemid 351679596)
18. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16(1):62-68.
19. van Wyk J, Qaqish R, Hollar K, Correll T, Norton M, King M. Baseline HIV-1 RNA does not affect virologic response to lopinavir/ritonavir-based regimens in antiretroviral-naive subjects: results of a 96-week metaanalysis of 2400 subjects [THPE0067]. Presented at: XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria.
20. Soulie C, Assoumou L, Ghosn J, et al. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. AIDS. 2009;23(12):1605-1608.